Adrenal cortex neoplasm

Summary

Adrenal cortex neoplasm (MONDO:0036591) is a cancer and 8 clinical trials. Top therapeutic interventions include axitinib, floxuridine, and tariquidar. A subtype of adrenal cortex disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• ClinVar variants: 1
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adrenal cortex neoplasm
Mondo ID	MONDO:0036591
MeSH	D000306
NCIT	C2858
UMLS	C0001618
MedGen	1350
GARD	0025820
Anatomy (UBERON)	UBERON:0001235
Is cancer (heuristic)	yes

Also known as: adrenal cortex neoplasm · adrenal cortex tumor · adrenal cortex tumour · adrenocortical neoplasm · adrenocortical tumor · adrenocortical tumour · neoplasm of adrenal cortex · tumor of adrenal cortex · tumour of adrenal cortex

Data availability: 1 ClinVar variant.

Disease family

This is a subtype of adrenal cortex disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › endocrine system disorder › adrenal gland disorder › adrenal cortex disorder › adrenal cortex neoplasm

Related subtypes (2): adrenocortical insufficiency, adrenal gland hyperfunction

Subtypes (3): adrenal cortex adenoma, familial hyperaldosteronism type II, malignant tumor of adrenal cortex

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 pathogenic; other

ClinVar	Variant (HGVS)	Gene	Classification	Review
17583	NM_001904.4(CTNNB1):c.98C>T (p.Ser33Phe)	LOC126806658	Pathogenic; other	no assertion criteria provided

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Mitotane	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05286814	PHASE2	RECRUITING	PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
NCT00071058	PHASE2	COMPLETED	Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
NCT01255137	PHASE2	COMPLETED	Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
NCT00700414	Not specified	RECRUITING	International Pediatric Adrenocortical Tumor Registry
NCT06050057	Not specified	RECRUITING	Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
NCT07072143	Not specified	RECRUITING	An International Study on Pediatric Patients With Rare Tumors.
NCT00768365	Not specified	COMPLETED	Cardiovascular Risk in Patients With Non-Functional Adrenal Incidentaloma
NCT02747355	Not specified	UNKNOWN	Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AXITINIB	4	1
FLOXURIDINE	4	1
TARIQUIDAR	3	1
CHEMBL3939307	0	1